Lifestyle and Medical Approaches to Cancer Prevention

  • Peter Greenwald
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 166)


Cancer risk can be reduced by adopting a healthy lifestyle and by medical means. Tobacco control is central to public policies for cancer prevention. Overweight and obesity in the United States may contribute to 20% of cancer deaths in women and 14% in men. Cancer prevention strategies have progressed from a predominant lifestyle approach to a model that combines clinical investigations in a medical setting with public health interventions. This change stems from advances in identifying, developing, and testing agents with the potential either to prevent cancer initiation, or to inhibit or reverse the progression of premalignant lesions to invasive cancer. Encouraging laboratory and epidemiologic studies, along with secondary endpoints in treatment trials, have provided a strong scientific rationale for the hypothesis that a pharmacologic approach—chemoprevention—can reduce cancer risk. Numerous chemopreventive agents, including naturally occurring vitamins, minerals, phytochemicals, and synthetic compounds, have proved to be safe and effective in preclinical and clinical studies. Promising results have been reported for cancers of the prostate, breast, colon, lung, bladder, cervix, oral cavity, esophagus, skin, and liver. The use of emerging technologies, identification of biomarkers of risk, and advances in genetic research are being applied to chemoprevention research. An interdisciplinary research approach to investigate molecular and genetic markers—as well as chemoprevention and lifestyle strategies—that affect cancer risk is being applied to the most common types of cancer in the United States in women (breast) and men (prostate).


Prostate Cancer Cancer Prevention Tobacco Control Medical Approach Reduce Cancer Risk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anthony M, Dunn BK, Sherman S (eds) (2001) Selective estrogen receptor modulators. Ann NY Acad Sci 949:1–427Google Scholar
  2. Brawley OW, Knopf K, Thompson I (1998) The epidemiology of prostate cancer part II: the risk factors. Semin Urol Oncol 16:193–201PubMedGoogle Scholar
  3. Buzdar A, O’shaughnessy JA, Booser DJ, Pippen JE Jr, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C (2003) Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 21:1007–1014PubMedCrossRefGoogle Scholar
  4. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr (1999) Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 341:1097–1105PubMedCrossRefGoogle Scholar
  5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638PubMedCrossRefGoogle Scholar
  6. Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL (1999) Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 8: 893–899PubMedGoogle Scholar
  7. Chemoprevention Working Group (1999) Prevention of cancer in the next millennium: report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res 59:4743–4758Google Scholar
  8. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957–1963PubMedCrossRefGoogle Scholar
  9. Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J (1998) Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 81:730–734PubMedGoogle Scholar
  10. Community Intervention Trial for Smoking Cessation (COMMIT) (1995) I. Cohort results from a four-year community intervention. Changes in adult cigarette smoking prevalence. Am J Public Health 85:183–192Google Scholar
  11. Doll R, Peto R (1981) The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66:1191–1308PubMedGoogle Scholar
  12. Fabian CJ (2001) Breast cancer chemoprevention: beyond tamoxifen. Breast Cancer Res 3:99–103PubMedCrossRefGoogle Scholar
  13. Fabian CJ, Kimler BF (2002) Breast cancer chemoprevention: current challenges and a look toward the future. Clin Breast Cancer 3: 113–124PubMedCrossRefGoogle Scholar
  14. Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA Jr, Brawley OW, Ford LG (1995) Design of the Prostate Cancer Prevention Trial (PCPT). Controlled Clin Trials 16:150–163PubMedGoogle Scholar
  15. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:371–388CrossRefGoogle Scholar
  16. GLOBOCAN (2000) Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5. IARCPress, Lyon. Web site at Scholar
  17. Greenwald P, Nixon DW, Malone WF, Kelloff GJ, Stern HR, Witkin KM (1990) Concepts in cancer chemoprevention research. Cancer 65: 1483–1490PubMedGoogle Scholar
  18. Greenwald P (2001) From carcinogenesis to clinical interventions for cancer prevention. Toxicology 166:37–45PubMedCrossRefGoogle Scholar
  19. Greenwald P (2002a) Cancer chemoprevention. BMJ 324:714–718PubMedCrossRefGoogle Scholar
  20. Greenwald P (2002b) Cancer prevention clinical trials. J Clin Oncol 20(18 Suppl): 14S–22SPubMedGoogle Scholar
  21. Greenwald P, Kelloff G, Burch-Whitman C, Kramer BS (1995) Chemoprevention. CA Cancer J Clin 45:31–49PubMedCrossRefGoogle Scholar
  22. Haiman CA, Stampfer MJ, Giovannucci E, Ma J, Decalo NE, Kantoff PW, Hunter DJ (2001) The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 10:743–748PubMedGoogle Scholar
  23. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK (1998) Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440–446PubMedCrossRefGoogle Scholar
  24. Higginson J (1988) Changing concepts in cancer prevention: limitations and implications for future research in environmental carcinogenesis. Cancer Res 48:1381–1389PubMedGoogle Scholar
  25. Hoque A, Albanes D, Lippman SM, Spitz MR, Taylor PR, Klein EA, Thompson IM, Goodman P, Stanford JL, Crowley JJ, Coltman CA, Santella RM (2001) Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control 12: 627–633PubMedCrossRefGoogle Scholar
  26. Huang M-T, Asawa T, Ho C-T, Rosen RT (eds) (1994) Food phytochemicals for cancer prevention I—fruits and vegetables, vol. 54. ACS Symposium Series No. 546, American Chemical Society: Washington, DC. Wiley, John and Sons, New York, pp1–426Google Scholar
  27. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC (2003) Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 54:131–152 (Epub 2001)PubMedCrossRefGoogle Scholar
  28. Kaluzny AD, Ricketts T 3rd, Warnecke R, Ford L, Morrissey J, Gillings D, Sondik EJ, Ozer H, Goldman J (1989) Evaluating organizational design to assure technology transfer: the case of the Community Clinical Oncology Program. J Natl Cancer Inst 81:1717–1725PubMedGoogle Scholar
  29. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, Coltman C (2001) SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. J Urol 166: 1311–1315Google Scholar
  30. Krishnamurthy S, Sneige N (2002) Molecular and biologic markers of premalignant lesions of human breast. Adv Anat Pathol 9:185–197PubMedGoogle Scholar
  31. Levin ML, Goldstein H, Gerhardt PR (1950) Cancer and tobacco smoking: a preliminary report. JAMA 143:336–338Google Scholar
  32. Li CI, Malone KE, Daling JR (2002) Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 11:601–607PubMedGoogle Scholar
  33. Manley M, Lynn W, Epps RP, Grande D, Glynn T, Shopland D (1997a) The American Stop Smoking Intervention Study for cancer prevention: an overview. Tob Control 6:S5–S11PubMedGoogle Scholar
  34. Manley MW, Pierce JP, Gilpin EA, Rosbrook B, Berry C, Wun LM (1997b) Impact of the American Stop Smoking Intervention Study on cigarette consumption. Tob Control 6 (Suppl 2): S12–S16PubMedGoogle Scholar
  35. McTiernan A (2003) Behavioral risk factors in breast cancer: can risk be modified? Oncologist 8:326–334PubMedCrossRefGoogle Scholar
  36. Mokbel K (2002) The evolving role of aromatase inhibitors in breast cancer. Int J Clin Oncol 7:279–283PubMedGoogle Scholar
  37. Negri E, La Vecchia CL, Franceschi S, D’Avanzo B, Parazzini F (1991) Vegetable and fruit consumption and cancer risk. Int J Cancer 48:350–354PubMedGoogle Scholar
  38. Pandey M, Mathew A, Nair MK (1999) Global perspective of tobacco habits and lung cancer: a lesson for third world countries. Eur J Cancer Prev 8:271–279PubMedGoogle Scholar
  39. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8: 307–325PubMedCrossRefGoogle Scholar
  40. Schwartz KL, Crossley-May H, Vigneau FD, Brown K, Banerjee M (2003) Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control 14:761–766PubMedCrossRefGoogle Scholar
  41. Shin BK, Wang H, Hanash S (2003) Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. J Mammary Gland Biol Neoplasia 7:407–413Google Scholar
  42. Steele VE (2003) Current mechanistic approaches to the chemoprevention of cancer. J Biochem Mol Biol 36:78–81PubMedGoogle Scholar
  43. Steele VE, Moon RC, Lubet RA, Grubbs CJ, Reddy BS, Wargovich M, McCormick DL, Pereira MA, Crowell JA, Bagheri D, Sigman CC, Boone CW, Kelloff GJ (1994) Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI chemoprevention drug development program. J Cell Biochem Suppl 20:32–54PubMedGoogle Scholar
  44. Stillman FA, Hartman AM, Graubard BI, Gilpin EA, Murray DM, Gibson JT (2003) Evaluation of the American Stop Smoking Intervention Study (ASSIST): a report of outcomes. J Natl Cancer Inst 95:1681–1691PubMedGoogle Scholar
  45. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224PubMedCrossRefGoogle Scholar
  46. Thun MJ, Henley SJ, Calle EE (2002) Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene 21:7307–7325PubMedCrossRefGoogle Scholar
  47. U.S. Department of Health and Human Services (1964) Smoking and health: a report of the Advisory Committee to the Surgeon General of the Public Health Service.U.S. Department of Health, Education, and Welfare, Centers for Disease Control, AtlantaGoogle Scholar
  48. U.S. Department of Health and Human Services (1998) Tobacco use among U.S. racial/ ethnic minority groups—African Americans, American Indians and Alaska natives, Asian Americans and Pacific islanders, and Hispanics: a report of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, AtlantaGoogle Scholar
  49. Verma M, Srivastava S (2003) New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res 163:72–84PubMedGoogle Scholar
  50. von Eschenbach AC (2003) NCI sets goal of eliminating suffering and death due to cancer by 2015. J Natl Med Assoc 95:637–639Google Scholar
  51. Wynder EL, Graham EA (1950) Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma. A study of 684 proved cases. JAMA 143:329–336Google Scholar
  52. Ye SQ, Usher DC, Zhang LQ (2002) Gene expression profiling of human diseases by serial analysis of gene expression. J Biomed Sci 9: 384–394PubMedCrossRefGoogle Scholar
  53. Yip TT, Lomas L (2002) SELDI ProteinChip array in oncoproteomic research. Technol Cancer Res Treat 1:273–280PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Peter Greenwald
    • 1
  1. 1.Division of Cancer PreventionNational Cancer Institute, National Institutes of HealthBethesdaUSA

Personalised recommendations